HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Kleerekoper, M. Search for Related Content PubMed PubMed Citation Articles by Kleerekoper, M. Related Collections Proteomics and Protein Markers

Biochemical Markers of Bone Turnover: Why Theory, Research, and Clinical Practice Are Still in Conflict

¹ Departments of Medicine and Pathology Wayne State University Detroit, MI 48201

^aAddress for correspondence. Endocrine Division, UHC-4H, 4201 St. Antoine, Detroit, MI 48201. E-mail m.kleerekoper@wayne.edu.

In metabolic bone diseases other than osteoporosis (Paget disease, rickets and osteomalacia, primary and secondary hyperparathyroidism), biochemical markers of bone turnover have been important clinical tools in patient management for more than 3 decades. In these diseases, bone metabolism is often so abnormal that even crude, nonspecific markers such as total serum alkaline phosphatase and urine hydroxyproline have been sufficiently reliable to allow clinicians to make appropriate management decisions without difficulty or error. When noninvasive measurements of bone mineral density (BMD) became available, the most common metabolic bone disease, osteoporosis, began to receive attention from researchers, pharmaceutical companies, and clinical practitioners. BMD technology from the beginning had very acceptable accuracy and precision errors such that diagnosis and monitoring of disease progression or regression were straightforward (1)(2). However, there was and remains one major drawback to BMD alone in the management of osteoporosis: bone turnover is generally so slow (particularly in relation to the other metabolic bone diseases listed above) that it may take up to 2 years in most circumstances to be certain with 95% confidence that any change in BMD is more than can be accounted for by method imprecision (3)(4)(5). When studying large groups of patients in a clinical trial, this is not a practical problem because significant group changes can be detected as early as 6 months after an intervention has been started (6)(7)(8)(9). This is of limited benefit to individual patient care.

To overcome this, researchers turned to biochemical markers of bone turnover as adjunctive tools in patient management. It became clear very early in this endeavor that total alkaline phosphatase and urine hydroxyproline lacked both the sensitivity and specificity to be of much value. Newer markers had . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				R. L. Fitzgerald, D. J. Hillegonds, D. W. Burton, T. L. Griffin, S. Mullaney, J. S. Vogel, L. J. Deftos, and D. A. Herold 41Ca and Accelerator Mass Spectrometry to Monitor Calcium Metabolism in End Stage Renal Disease Patients Clin. Chem., November 1, 2005; 51(11): 2095 - 2102. [Abstract] [Full Text] [PDF]

				A. C. Looker The Skeleton, Race, and Ethnicity J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3047 - 3050. [Full Text] [PDF]